

*The National Academies of*  
SCIENCES • ENGINEERING • MEDICINE

**Standing Committee on Emerging Infectious Diseases  
and 21<sup>st</sup> Century Health Threats**

**Workshop on Allocation of COVID-19 Monoclonal Antibody  
Therapies and Other Novel Therapeutics  
*Final Agenda***

**December 16-17, 2020  
10:00 a.m. – 2:00 p.m. ET  
Zoom Webinar**

**Workshop Objectives**

- Discuss key considerations for assisting decision makers in their efforts to equitably allocate COVID-19 monoclonal antibody therapies and other novel therapeutics at the state and local levels
- Examine related key issues such as barriers to access, particularly for populations at high risk for serious COVID-19-related outcomes, administration capacity, cost, and data collection and reporting

**Day 1 – December 16, 2020**

---

**SESSION I: Welcome and Opening Remarks to Day 1**

- 10:05 a.m.    **Welcome and Meeting Objectives**  
*Harvey Fineberg, Standing Committee Chair*  
President  
Gordon and Betty Moore Foundation
- 10:10 a.m.    **Opening Remarks**  
*Victor Dzau*  
President  
National Academy of Medicine

10:15 a.m.     **Opening Remarks**  
                    *Robert Kadlec*  
                    Assistant Secretary for Preparedness and Response  
                    Department of Health and Human Services

## SESSION II: Overview and Background

Session Moderator: *Kent Kester, Standing Committee Member*

Session Objectives: To provide a shared understanding of the current state of efforts around the allocation of COVID-19 monoclonal antibody therapies from the policy-level perspective.

10:20 a.m.     **Brief Overview of COVID-19 Monoclonal Antibody Allocation Considerations at the Federal Level**  
                    *John Redd*  
                    Chief Medical Officer  
                    Office of the Assistant Secretary for Preparedness and Response  
                    Department of Health and Human Services

10:35 a.m.     **Right Patient, Right Time, Right Place: A Critical Challenge of COVID-19 Monoclonal Antibodies**  
                    *Marta Wosinska*  
                    Consulting Professor  
                    Deputy Director, Policy  
                    Duke-Margolis Center for Health Policy

10:50 a.m.     **Other Policy-Level Perspectives**  
                    *Michael Ganio*  
                    Senior Director, Pharmacy Practice and Quality  
                    Center on Medication Safety and Quality  
                    American Society of Health-System Pharmacists

*Michael Wargo*  
                    Vice President of Emergency Preparedness  
                    HCA Healthcare  
                    Acting Chair  
                    U.S. Healthcare and Public Health Sector Coordinating Council

*Mark Jarrett*  
                    Senior Vice President and Chief Quality Officer  
                    Northwell Health

11:15 a.m.     **Moderated Discussion with Panelists**

11:45 a.m.     **Lunch / Break**

## SESSION III: On-the-Ground Perspectives

Session Moderator: *John Hick, Standing Committee Member*

Session Objectives: To discuss the different frameworks being used to allocate COVID-19 monoclonal antibody therapies and other novel therapeutics at the state and local levels and to discuss first-hand experiences, challenges, successes, and lessons learned.

12:15 p.m.     **State and Local Stakeholders**

*Jeff Gumprecht*

Associate Professor of Infectious Disease  
Mount Sinai Health System

*Eric France*

Chief Medical Officer  
Colorado Department of Public Health and Environment

*Mohammad Kharbat*

Vice President  
Pharmacy Services and Health Research  
SSM Health—Wisconsin Region

*Megan Klatt*

Infectious Diseases Pharmacy Resident  
University of Michigan School of Medicine

*Trisha Jordan*

Director of Pharmacy Clinical Services  
The Ohio State University Wexner Medical Center

*Lawrence Madoff*

Medical Director  
Bureau of Infectious Disease and Laboratory Sciences  
Massachusetts Department of Public Health

*John Sanders*

Head, Infectious Disease Section  
Wake Forest Baptist Health System

*Emily Sydnor Spivak*

Associate Professor of Medicine  
Division of Infectious Diseases  
University of Utah

1:00 p.m.     **Moderated Discussion with Panelists**

## SESSION IV: Day 1 Wrap Up

- 1:45 p.m.      **Wrap Up and Summarize Day 1**  
*Harvey Fineberg, Standing Committee Chair*  
President  
Gordon and Betty Moore Foundation
- 2:00 p.m.      **Adjourn Day 1**

## Day 2 – December 17, 2020

---

## SESSION V: Welcome to Day 2

- 10:00 a.m.      **Welcome and Introduction to Day 2**  
*Harvey Fineberg, Standing Committee Chair*  
President  
Gordon and Betty Moore Foundation

## SESSION VI: Access and Equity Considerations

Session Moderator: *Alta Charo, Standing Committee Member*

Session Objectives: To discuss the specific considerations related to key issues of access and equity, particularly for marginalized populations.

- 10:05 a.m.      **Issues of Access and Equity**  
*Robert Goldstein*  
Medical Director  
Transgender Health Program  
Massachusetts General Hospital
- Keith Boell*  
Chief Quality Officer for Population Initiatives  
Geisinger Health System
- Christian Ramers*  
Medical Director, Laura Rodriguez Research Institute  
Chief, Population Health  
Director, Graduate Medical Education  
Family Health Centers of San Diego
- Andrew Shuman*  
Associate Professor, Division of Head and Neck Oncology

University of Michigan Health System  
Co-Chief, Clinical Ethics Service  
Center for Bioethics and Social Sciences in Medicine  
University of Michigan Medical School

*Abigail Echo-Hawk (Citizen of the Pawnee Nation)*  
Director  
Urban Indian Health Institute  
Chief Research Officer  
Seattle Indian Health Board

*Nneka Sederstrom*  
Director  
Clinical Ethics Department  
Children's Hospitals and Clinics of Minnesota

*Robyn Stone*  
Senior Vice President for Research  
LeadingAge

*Connie Sullivan*  
President and CEO  
National Home Infusion Association

*Douglas White*  
Vice Chair and Professor of Critical Care Medicine, UPMC Endowed  
Chair for Ethics in Critical Care Medicine  
Director, Program on Ethics and Decision Making in Critical Illness  
University of Pittsburgh School of Medicine

*Govind Persad*  
Assistant Professor  
Sturm College of Law  
University of Denver

11:00 a.m.     **Moderated Discussion with Panelists**

12:00 p.m.     **Lunch / Break**

## SESSION VII: Other Considerations

Session Moderator: *Donald Berwick, Standing Committee Member*

Session Objectives: To discuss the other considerations surrounding the implementation of allocating COVID-19 monoclonal antibody therapies and other novel therapeutics.

12:30 p.m.     **Key Consideration: Cost**

*Marianne Hamilton Lopez*  
Research Director of Value-Based Payment Reform  
Duke-Margolis Center for Health Policy

*Anna Kaltenboeck,*  
Senior Health Economist and Program Director  
Drug Pricing Lab  
Center for Health Policy and Outcomes  
Memorial Sloan Kettering Cancer Center

*Brian Nyquist*  
President and CEO  
National Infusion Center Association

12:45 p.m.     **Key Consideration: Manufacturing Capacity to Scale Up Supply**

*Andrew Adams*  
Vice President  
New Therapeutic Modalities  
Eli Lilly

*Ronald Cobb*  
Chief Scientific Officer  
Ology Bioservices, Inc.

12:55 p.m.     **Key Consideration: Other Issues**

### **Evidence Generation / Data Considerations**

*Sameer Awsare*  
Associate Executive Director  
The Permanente Medical Group

*Natalie Dean*  
Assistant Professor of Biostatistics  
University of Florida

### **Global and International Issues**

*Mark Feinberg*  
President and CEO  
International AIDS Vaccine Initiative (IAVI)

*Charlotte Taylor*  
Acting Director, Therapeutics Taskforce  
United Kingdom Department of Health and Social Care

1:20 p.m.      **Moderated Discussion with Panelists**

## **SESSION VIII: Day 2 Wrap Up**

1:45 p.m.      **Closing Remarks**  
*Harvey Fineberg, Standing Committee Chair*  
President  
Gordon and Betty Moore Foundation

2:00 p.m.      **Adjourn Day 2**